MGF
Mechano Growth Factor | IGF-1 Splice Variant
Non-pegylated IGF-1 splice variant produced locally in muscle tissue following mechanical stress. Has a very short half-life compared to PEG-MGF, requiring more frequent administration or localized injection.
Mechanism of Action
Activates muscle satellite stem cells via receptor binding, stimulating MAPK/ERK signaling. Enhances protein synthesis and promotes muscle fiber repair. The E-peptide domain exhibits distinct activity from mature IGF-1.
Key Benefits
- Satellite cell activation for muscle repair
- Recovery support following mechanical stress
- Localized tissue regeneration
- Natural upregulation after exercise
YQPPSTNKNTKSQRRKGSTFEEHK Complex or non-standard sequence format
Muscle Repair
- Satellite Cell Activation
Primary mechanism activating dormant muscle satellite cells which fuse to damaged fibers.
- Local Muscle Recovery
Short half-life means effects are concentrated at injection site.
- Post-Exercise Recovery
Naturally upregulated after mechanical stress; supplementation enhances repair processes.
Tissue Regeneration
- Tendon Healing
Animal studies suggest improved tendon injury outcomes when applied locally.
- Bone Regeneration
Research indicates potential for bone healing via osteoblast regulation.
Intramuscular injection directly into target muscle immediately post-workout for localized effects due to short half-life.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard Protocol | 100-300mcg | Daily, post-workout | IM into target muscle |
| Progressive Titration | 100mcg → 300mcg | Daily, increasing weekly | IM bilateral |
| Localized Recovery | 200-300mcg | Immediately post-workout | IM into worked muscle groups |
Reconstitution Instructions
- MGF lyophilized powder (typically 5mg vial)
- Bacteriostatic water (3.0mL recommended)
- Insulin syringes (29-31 gauge)
- Alcohol swabs
- 1 Allow vial to reach room temperature
- 2 Clean rubber stopper with alcohol swab
- 3 Add 3.0mL bacteriostatic water for ~1.67mg/mL concentration
- 4 Inject slowly along vial wall, not directly onto powder
- 5 Gently swirl to dissolve; never shake
- 6 Store refrigerated at 2-8°C
- 7 Use within 30 days of reconstitution
Same active peptide with different half-lives. Combining is redundant; choose one based on protocol preference.
Both target IGF-1 pathways; combining risks receptor overstimulation.
Complementary mechanisms. BPC-157 promotes angiogenesis; MGF activates satellite cells.
TB-500 reduces inflammation and promotes cell migration; MGF activates muscle stem cells.
Very short half-life means localized effects at injection site within minutes
Reduced muscle soreness in targeted areas; subtle recovery improvements
Improved recovery in targeted muscles; enhanced training capacity
Common Side Effects
- Injection site soreness
- Mild fatigue
Stop Signs - Discontinue if:
- Any unusual growths, lumps, or rapid tissue changes
- Severe injection site reactions
- Persistent headaches or vision changes
- Signs of hypoglycemia
Contraindications
- Any history of cancer or neoplastic disease
- Pregnancy or breastfeeding
- Uncontrolled diabetes
Good Signs
- White or off-white fluffy cake appearance
- Crystal clear solution after reconstitution
- Certificate of Analysis with HPLC purity >98%
Warning Signs
- Minor clumping that dissolves with gentle swirling
Bad Signs
- Collapsed or discolored powder
- Persistent cloudiness or visible particles
- MGF-E Peptide Human Muscle Cell Study(2011)
MGF significantly increased satellite cell proliferation at 3ng/ml with age-dependent effects.
- Mechano-Growth Factor Minireview(2010)
Overview of MGF as IGF-I gene product involved in tissue repair, upregulated following exercise and injury.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.